JAN (JAN) Stock Price, News & Analysis

Company Overview

JanOne Inc. (NYSE: JAN) is a social-impact and technology company focused on addressing the opioid crisis. Its activities have included the development and commercialization of solutions intended to support opioid-related treatment and prevention, with an emphasis on using business and technology to promote measurable social benefits.

Through its subsidiaries and related operations, JanOne has also pursued financial technology initiatives, including blockchain-based payment and transaction solutions. These offerings are designed to support digital-asset payments and other financial applications for businesses and consumers.

JanOne is based in the United States and has positioned its business around combining life-sciences initiatives with financial technology and social-impact programs. The company has operated under the JanOne name following earlier corporate and strategic changes, although the scope and status of its individual programs may evolve over time.

Key Stats

• Today's Range: $27.99 to $29.00
• 50-Day Range: $27.79 to $31.83
• 52-Week Range: $22.76 to $32.83
• Volume: 1.44 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $8.25 billion
• P/E Ratio: N/A
• Dividend Yield: 2.02%
• Price Target: $32.31
• Consensus Rating: Moderate Buy

JAN Stock Analysis - MarketRank™

JAN scored higher than 77% of companies evaluated by MarketBeat, and ranked 64th out of 188 stocks in the real estate sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

JAN has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 12 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

JAN has a consensus price target of $32.31, representing about 14.3% upside from its current price of $28.28.

Amount of Analyst Coverage

JAN has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 23.71%

Earnings Growth

Earnings for JAN are expected to grow by 23.71% in the coming year, from $0.97 to $1.20 per share.

Price to Earnings Growth Ratio

JAN has a PEG Ratio of 1.12. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.91% of the float of JAN has been sold short.

Short Interest Ratio / Days to Cover

JAN has a short interest ratio ("days to cover") of 4.68.

Change versus previous month

Short interest in JAN has recently increased by 36.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

JAN pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

JAN does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, JAN will have a dividend payout ratio of 47.50% next year. This indicates that JAN will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 1.78

News Sentiment

JAN has a news sentiment score of 1.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Real Estate companies.

News Coverage This Week

MarketBeat has tracked 70 news articles for JAN this week, compared to 17 articles on an average week.

Search Interest

5 people have searched for JAN on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added JAN to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, JAN insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.00% of the stock of JAN is held by insiders.

Percentage Held by Institutions

6.27% of the stock of JAN is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Record date for 10/28 Dividend: 10/16/2026
• Ex-Dividend for 10/28 Dividend: 10/16/2026
• Today: 10/25/2026
• Dividend Payable: 10/28/2026
• Next Earnings (Confirmed): 11/02/2026
• Record date for 11/23 Dividend: 11/12/2026
• Ex-Dividend for 11/23 Dividend: 11/12/2026
• Dividend Payable: 11/23/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Real Estate
• Industry: Healthcare REITs
• Sub-Industry: Healthcare REITs
• Current Symbol: NYSE:JAN
• CIK: 2100805
• Web: janusreit.com
• Phone: (720) 428-5050
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for JAN: $32.31
• High Price Target: $37.00
• Low Price Target: $27.00
• Potential Upside/Downside: +14.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 29.16
• P/E Growth: 1.12
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.46
• Quick Ratio: 5.46

Sales & Book Value

• Annual Sales: $603.99 million
• Price / Sales: 13.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 291,890,000
• Free Float: 283,134,000
• Market Cap: $8.25 billion
• Optionable: Optionable
• Beta: N/A